Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test

被引：2
|
作者：
Ishido, Shun [1 ]
Tamaki, Nobuharu [1 ]
Inada, Kento [1 ]
Itakura, Jun [1 ]
Takahashi, Yuka [1 ]
Uchihara, Naoki [1 ]
Suzuki, Keito [1 ]
Tanaka, Yuki [1 ]
Miyamoto, Haruka [1 ]
Yamada, Michiko [1 ]
Matsumoto, Hiroaki [1 ]
Nobusawa, Tsubasa [1 ]
Keitoku, Taisei [1 ]
Takaura, Kenta [1 ]
Tanaka, Shohei [1 ]
Maeyashiki, Chiaki [1 ]
Yasui, Yutaka [1 ]
Tsuchiya, Kaoru [1 ]
Nakanishi, Hiroyuki [1 ]
Kurosaki, Masayuki [1 ,2 ]
Izumi, Namiki [1 ]
机构：
[1] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan
[2] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan
来源：
CLINICAL CASE REPORTS | 2023年 / 11卷 / 07期
关键词：
comprehensive genomic profiling; fibroblast growth factor receptor 2; intrahepatic cholangiocarcinoma; pemigatinib; PHASE-II; MULTICENTER; GEMCITABINE; CISPLATIN; S-1;
D O I：
10.1002/ccr3.7664
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Key Clinical MessageThe liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
    Mazzaferro, Vincenzo
    El-Rayes, Bassel F.
    Busset, Michele Droz Dit
    Cotsoglou, Christian
    Harris, William P.
    Damjanov, Nevena
    Masi, Gianluca
    Rimassa, Lorenza
    Personeni, Nicola
    Braiteh, Fadi
    Zagonel, Vittorina
    Papadopoulos, Kyriakos P.
    Hall, Terence
    Wang, Yunxia
    Schwartz, Brian
    Kazakin, Julia
    Bhoori, Sherrie
    de Braud, Filippo
    Shaib, Walid L.
    BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 165 - 171
  • [32] Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
    Walden, Daniel
    Eslinger, Cody
    Bekaii-Saab, Tanios
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
  • [33] Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
    Busset, M. Droz Dit
    Braun, S.
    El-Rayes, B.
    Harris, W. P.
    Damjanov, N.
    Masi, G.
    Rimassa, L.
    Bhoori, S.
    Niger, M.
    Personeni, N.
    Braiteh, F.
    Lonardi, S.
    Engelhardt, M.
    Saulay, M.
    Schwartz, B.
    Shaib, W. L.
    Mazzaferro, V.
    Papadopoulos, K. P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [34] Novel FGFR2 biparatopic antibodies for the treatment of cholangiocarcinoma
    Chaturantabut, Saireudee
    Oliver, Sydney
    Kim, John
    Frederick, Dennie
    Robinson, Foxy
    Sinopoli, Alessandro
    Rodriguez, Diego J.
    Chang, Liang
    Bardeesy, Nabeel
    Sellers, William
    CANCER RESEARCH, 2023, 83 (07)
  • [35] FGFR2 Alterations in Primary Intrahepatic Cholangiocarcinoma: Driving New Routes for Therapy
    Mirchia, Kanish
    Gay, Laurie
    Elvin, Julia
    Vergilio, Jo-Anne
    Killian, J. Keith
    Nhu Ngo
    Ramkissoon, Shakti
    Severson, Eric
    Hemmerich, Amanda
    Chung, Jon
    Ali, Siraj
    Schrock, Alexa
    Reddy, Venkataprasanth
    Miller, Vincent
    Corona, Robert
    Ross, Jeffrey
    MODERN PATHOLOGY, 2019, 32
  • [36] FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH
    Zhang, Xin
    Bai, Qianming
    Wang, Yulin
    Jiang, Zhengzeng
    Han, Jing
    Xue, Cheng
    Huang, Kai
    Luan, Lijuan
    Huang, Xiaoyong
    Huang, Xiaowu
    Shi, Guoming
    Hou, Yingyong
    Ji, Yuan
    VIRCHOWS ARCHIV, 2025,
  • [37] FGFR2 Alterations in Primary Intrahepatic Cholangiocarcinoma: Driving New Routes for Therapy
    Mirchia, Kanish
    Gay, Laurie
    Elvin, Julia
    Vergilio, Jo-Anne
    Killian, J. Keith
    Nhu Ngo
    Ramkissoon, Shakti
    Severson, Eric
    Hemmerich, Amanda
    Chung, Jon
    Ali, Siraj
    Schrock, Alexa
    Reddy, Venkataprasanth
    Miller, Vincent
    Corona, Robert
    Ross, Jeffrey
    LABORATORY INVESTIGATION, 2019, 99
  • [38] FGFR2 in-frame indels: A novel targetable alteration in intrahepatic cholangiocarcinoma
    Li, Yvonne Y.
    Cleary, James M.
    Raghavan, Srivatsan
    Spurr, Liam F.
    Wu, Qibiao
    Shi, Lei
    Brais, Lauren K.
    Loftus, Maureen
    Goyal, Lipika
    Patel, Anuj K.
    Shinagare, Atul B.
    Clancy, Thomas E.
    Shapiro, Geoffrey
    Cerami, Ethan
    Sellers, William R.
    Hahn, William C.
    Meyerson, Matthew
    Bardeesy, Nabeel
    Cherniack, Andrew D.
    Wolpin, Brian M.
    CANCER RESEARCH, 2020, 80 (16)
  • [39] A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
    Zhang, Lei
    Zheng, Hao
    Xu, Linyu
    You, Si
    Shen, Yuanyuan
    Han, Yang
    Anderson, Steve
    DIAGNOSTICS, 2023, 13 (12)
  • [40] FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma
    Mahipal, Amit
    Tella, Harsha
    Kommalapati, Anuhya
    Anaya, Daniel
    Kim, Richard
    CANCER TREATMENT REVIEWS, 2019, 78 : 1 - 7
12345